為提供您最佳個人化且即時的服務，本網站透過使用"Cookies"記錄與存取您的瀏覽使用訊息。當您使用本網站，即表示您同意Cookies技術支援。更多資訊請參閱隱私權條款及Cookies說明。 登入說明：本站使用開放授權登入。 (C) 1. �~�F�аO(tumor markers)�����ΡA�i�B�Φb�c�ʸ~�F���v�������A�@���v�����Ī����U�����C�H�U�U�ظ~�F�аO�P�~�F���t��A���ǬO���T��? (1)catecholamines�Ppheochromocytoma (2)calcitonin�Ppapillary cancer of the thyroid (3)human chorionic gonadotropin (hCG)�Pgestational trophoblastic disease (4)�\-fetoprotein�Pgonadal germ cell tumor A. (1)+(2)+(3) B. (1)+(2)+(4) C. (1)+(3)+(4) D. (2)+(3)+(4) E. (1)+(2)+(3)+(4) (D) 2. �\�h�c�ʸ~�F�`���P����](oncogene)�����ܩά��ơC�H�U�U�حP����]�����ܻP���g���t��A���ǬO���T��? (1)BRAF point mutation�Pmelanoma (2)CTNNB1 point mutation�Pprostate cancer (3)FOS overexpression�Posteosarcomas (4)ERBB2 amplification��point mutation�Pcolon cancer (5)N-MYC amplification�Pneuroblastoma A. (1)+(2)+(3)+(4) B. (2)+(3)+(4)+(5) C. (1)+(2)+(4)+(5) D. (1)+(2)+(3)+(5) E. (1)+(2)+(3)+(4)+(5) (D) 3. �G�z�D���w�����i��ǩʪ�(hereditable)�h�o���ׯg�Ըs(polyposis syndrome)�A�Ʀܦ��c�ʤƪ��i���(malignant potential)�C�䤤���Ǧh�o���ׯg�Ըs�A���פ������f�z�ˬd��adenoma�A�t�~���ǯg�Ըs���פ������פ��f�z��´�ˬd�h��hamartoma�C�U�C��� "�i��ǩʦh�o���ׯg�Ըs" �h�b�z�D�o�͡A�B���פ������f�z�ˬd��adenoma? (1)Familial adenomatous polyposis (FAP) (2)Gardner's syndrome (3)Turcot's syndrome (4)Peutz-Jeghers syndrome (5)Lynch syndrome A. (1)+(2)+(3)+(4) B. (2)+(3)+(4)+(5) C. (1)+(3)+(4)+(5) D. (1)+(2+(3)+(5) E. (1)+(2)+(3)+(4)+(5) (B) 4. 65���s�E�_�����f�H�A���e���騭�骬�p�}�n�A�L��ۨ�L�@�f(co-morbidities)�f�v�A�gmodified radical mastectomy��N�����k�������P�k���ŤU�O�ڵ����M�N�A�f�z�ˬd��ܨ����~���j�p4�����A�ŤU�O�ڵ�15������10���w�������ӭM�I�ǡA�V��ER(-)�BPR(-)�BHER2(-)�C�A��ij������ؤ�N�Ỳ�U��(adjuvant)�v���ӭ��C���g�_�o? A. tamoxifen B. multi-drug chemotherapy C. aromatase inhibitors D. trastuzumab E. no indications for adjuvant therapy (B) 5. �L�k��N�����B�L�k�i��ʯ߮��v�����ߴ��x��(HCC)�f�H�A�йv�v���Ī�(targeted agents)��~�w�����n���i�i�C�U�C��̬��Q�ҹ꦳�Ĥ��ߴ��x�����Ĥ@�Ӥf�A�йv�Ī�? �g�ѲĤT��(Phase III)�{�ɸ����ҹ��Child-Pugh A���ߴ��x���f�H�Ĥ@�u�ϥήɡA������s�����ɮĪG�A�ثe�w�Q�����ߴ��x��standard of care���@�C A. sunitinib B. sorafenib C. brivanib D. everolimus E. erlotinib (D) 6. �G�H�������O����(MALT lymphoma)���ͦ��P�G�ժ����۱��(H. pylori)�K�������A�]�w��MALT lymphoma���`���V�����ܤ�(cytogenetic translocation)���y��API2/MALT�PBcl-10���P���]�l�����ơC�GMALT lymphoma�̱`�����V��������ܤƬ���? A. t(14;15) (q32;q13) B. t(9;22) (q34;q11) C. t(4;11) (q21;q23) D. t(11;18) (q21;q21) E. t(2;5) (p23;q35) (E) 7. ��o���줣�����ಾ�ʤW����(carcinoma of unknown primary, CUP)�A�f�z��´�`�ݭn�B�~�i��K�̲�´�V��(immunohistochemical stains)�A�����{�ɤW�������g���x��o�ӷ����ѦҨ̾ڡCcytokeratin(CK)�O�g�`�ϥΪ�intermediate filaments�V��A�H�馳20�h��CK�ȫ��A��������ӭMCK20�V��ʥBCK7�V�⳱��(CK20+/ CK7-)�ɡA�۹�CUP�̥i���o���x���U�C���? A. lung B. breast C. endometrium D. pancreas E. colon (B) 8. �ಾ�ʤj�z���b�ϥΧ����Ī��v���ɡA�w�����@���n���w���ʥͪ��аO(predictive biomarker)�CĴ�p:���j�z������K-RAS��codon 12��]���ݡu���ܫ��v�ɡA��U�C�����ľ�����u�L�ġv(non-responsiveness)�A�]������ij��θ��ľ��v���C A. Bevacizumab (VEGF monoclonal antibody) B. Cetuximab (EGFR monoclonal antibody) C. 5-fluorouracil (5-FU) D. Oxaliplatin E. Irinotecan (CPT-11) (C) 9. ����testicular cancer����non-seminoma�Pseminoma��j�զ��A�B�w����㦳�t�O�C�U�C��ئ�M�~�F�аO(tumor marker)��ۤW�ɮɡA�N���ӯf�H��testicular cancer���w���unon-seminoma�v����? A. LDH (lactate dehydrogenase) B. beta-hCG (human chorionic gonadotropin) C. AFP (�\-fetoprotein) D. ALP (alkaline phosphatase) E. ALT (alanine aminotransferase) (B) 10. ���g�����c�~�F(neuroendocrine tumors)����"����"(carcinoid tumor)���ɥH���m(diarrhea)�B���(flushing)�A�Ʀܰ}�o�ʯk�h�B��ݵ�"�����g�Ըs"(carcinoid syndrome)�Ӫ��{�A�M�����Ҥ��c��serotonin�Btachykinins�Bmotilin�����ʪ��観���C�q�`���{"�����g�Ըs"��"����"�~�F��m(location)�۹�̦h�ư_����F�L�Ǫ����ӳ���? A. Foregut B. Midgut C. Hindgut D. Foregut�BMidgut�BHindgut ���{"�����g�Ըs"�����|���۪� E. Rectum |
與乳癌有關的腫瘤標記tumor markers下列何者正確
版權 © 2024 zh.apacode Inc.
